We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.
We are looking for D/P's in the following categories:
| ID # | Required D/P's | Enrolled D/P's | Remaining D/P's | Inclusion Criteria |
|---|---|---|---|---|
| 378014 | 80 | 0 | 80 | Pre-Selected Negative Serum Samples from Major Ethnicity Groups |
| 377942 | 25 | 0 | 25 | Vaginal Swab and Urine Samples from CT Positive Donors |
| 377709 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Blood, finger stick, Endocervical, Vaginal, Nasal, Pharyngeal, Rectal, Urethral and/or Urine Specimens. |
| 377562 | 500 | 0 | 500 | Vaginal Swab Samples from Suspected HPV Donors_SRF_0003720 |
| 377543 | 224 | 0 | 224 | Vaginal Swab Samples from Healthy Donors_SRF_00033656 |
| 377513 | 10 | 0 | 10 | HHV7 IgG Positive Samples from Inventory |
| 377405 | 1 | 0 | 1 | Prospective Whole Blood Collection from a HxV Negative Donor_SRF_0003781/SACQ_0003493 |
| 377308 | 132 | 0 | 132 | Urine Samples from Symptomatic Donors_SRF_00033656 |
| 377054 | 700 | 0 | 700 | Serum Samples from Donors with FT4 results from IRL. |
| 376909 | 310 | 0 | 310 | Prospective Serum Collection from Healthy Pediatric Cohorts - Healthy based health check questionnaire - Age:10-20 years old - BMI: 5th percentile- 85th percentile |
| 376553 | 1000 | 0 | 1000 | Prospective Whole Blood Collection from HxV Negative Donors in Streck Tubes |
| 376550 | 15 | 0 | 15 | Pre-Selected HCV Positive Samples with High Viral Load from Inventory |
| 376237 | 24 | 0 | 24 | Female Vaginal Sample Collection Protocol for Panel Development |
| 376198 | 1000 | 0 | 1000 | Remnant SARS-CoV-2, Flu A, Flu B and RSV Negative Nasopharyngeal Swabs from Inventory |
| 376011 | 10 | 0 | 10 | Pre-selected HIV-1 and HIV-2 Co-Infected Positive Samples from Inventor |
| 375810 | 120 | 0 | 120 | Pre-Selected Serum Samples from Inventory_Lp(a) - Cardiac Marker Project |
| 375620 | 17 | 0 | 17 | Pre-Selected HCV High Viral Load PPT Plasma Samples from Inventory_ BD PPT Study (PAS-19SUST055). |
| 375590 | 20 | 0 | 20 | Pre-Selected HBV High Viral Load PPT Plasma Samples from Inventory_BD PPT Study (PAS-19SUST053) |
| 375572 | 22 | 0 | 22 | Pre-Selected HIV High Viral Load PPT Plasma Samples from Inventory_ BD PPT Study (PAS-19SUST046). |
| 374419 | 21 | 0 | 21 | Pre-Selected STI Positive Serum Samples from Inventory |
| 373958 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Endocervical, Vaginal, Nasal, Pharyngeal, Rectal, Urethral and/or Urine Specimens |
| 373935 | 20 | 0 | 20 | Prospective ACD fresh whole blood from healthy donors - In BD #364606 - Non Smokers - Normal Glucose Patients - lean (normal BMI_Healthy Weight) - 60 years and older |
| 373582 | 200 | 0 | 200 | Plasma, Serum, and Saliva samples from donors with fever from Colombia |
| 373511 | 100 | 0 | 100 | HBsAg, HIV-Ag, and HCV-Ag cassette evaluation using fresh whole blood samples and fresh whole blood spiked samples. |
| 373102 | 10000 | 0 | 10000 | A Multi-Site, Point in Time, Prospective Collection Protocol in order to obtain Nasal Swab, Pharyngeal Swab, and/or Blood Samples from Pediatric D/Ps (Donor/Participants). |
| 372833 | 150 | 0 | 150 | Prospective collection from Healthy Donors |
| 372734 | 400 | 0 | 400 | Prospective Serum Remnant Samples from STI Tested Donors |
| 372347 | 100 | 0 | 100 | Pre-Selected Remnant Flu A/B, RSV, SARS-CoV-2 Negative NPS_TZ0144602/SRF_0003594 |
| 370492 | 1000 | 0 | 1000 | Prospective Collection Symptomatic Donors One or more flu-like symptoms such as: fever, cough, sore throat, runny or stuffy nose, muscle or body aches, headache, fatigue, vomiting, or diarrhea, with symptom onset within the past 7 calendar days AND/OR One or more COVID-19 symptoms such as: fever, dry cough, fatigue, loss of appetite, loss of smell or taste, body ache, or shortness of breath, with symptom onset within the past 7 calendar days AND/OR Subject has had a rapid positive COVID-19, flu A or flu B result in the past 48 hours, and symptom onset occurred within the past 4 calendar days, OR Subject has had a rapid positive COVID-19, flu A, or flu B result in the past 48 hours and has not experienced symptom onset to date. |
| 369631 | 200 | 0 | 200 | Prospective Rectal Swab Collection from Ct/Ng Symptomatic Donors |
| 369316 | 1000 | 0 | 1000 | Prospective Remnant Vaginal Swab Samples from Symptomatic Donors after Hologic SOC testing. |
| 369311 | 100 | 0 | 100 | HPV Genotyping Testing Service on Hologic Panther System |
| 368383 | 965 | 0 | 965 | HSV-2 IgG Double Testing on Bioplex at IRL and Elecsys at UM. |
| 368317 | 4 | 0 | 4 | Endocervical Swab from Healthy Donors (SRF_0003624) SACQ_00003393 |
| 367757 | 100 | 0 | 100 | HPV DNA Testing Service on Hologic Panther System |
| 367165 | 100 | 0 | 100 | Prospective Collection of Plasmodium Positive Donors from Guinea Bissau |
| 366644 | 5000 | 9 | 4991 | Refer to Processing Instructions @ Attachment Tab |
| 365916 | 140 | 98 | 42 | Serum Samples from Donors with TT4 results. |
| 364231 | 100 | 27 | 73 | Serum Samples from Cadaveric Donors_RQST 8856 |
| 363840 | 20 | 19 | 1 | Pre-Selected HBV High Viral Load PPT Plasma Samples from Inventory_BD PPT Study (PAS-19SUST052) |
| 363839 | 17 | 17 | 0 | Pre-Selected HCV High Viral Load PPT Plasma Samples from Inventory_ BD PPT Study (PAS-19SUST054). |
| 363837 | 22 | 21 | 1 | Pre-Selected HIV High Viral Load PPT Plasma Samples from Inventory_ BD PPT Study (PAS-18SUST033). |
| 363014 | 200 | 151 | 49 | Vaginal Swab Collection from Asymptomatic Female Donors_TZC0150984/SRF_0003609 |
| 362981 | 2 | 2 | 0 | Vaginal Swab Collection from Yeast Infection Symptomatic Female Donors. |
| 362487 | 170 | 0 | 170 | Prospective Serum Samples Collection from Healthy Donors _ TZC0145085. |
| 362427 | 200 | 125 | 75 | Vaginal Swab Collection from Symptomatic Female Donors_TZC0150984/SRF_0003609 |
| 362249 | 46 | 46 | 0 | Lyme IgG and Lyme IgM Testing in the Liaison XL |
| 361569 | 100 | 477 | -377 | Pre-Selected HxV NAT Negative K3EDTA Plasma samples from Inventory (Pooled Material)_SRF_0003267 SACQ_0003330. |
| 360643 | 250 | 39 | 211 | Samples testing protocol for TSH3, aTG, and aTPO Testing in BCW-PR |
| 357239 | 1200 | 459 | 741 | Whole Blood, Serum and Plasma samples for HbA1C, Creatinine and BNP Testing in BCW-PR |
| 355419 | 1500 | 0 | 1500 | cobas® MPLX Respiratory for use on cobas® 5800/6800/8800 Systems: Reproducibility Study_ cX8-MPLX-584 _ RD006809 |
| 354307 | 80 | 165 | -85 | Clinical Evaluation of the Xpert® Respiratory Panel for Adenovirus Detection, Cepheid 263C1-C3 |
| 350630 | 10000 | 207 | 9793 | Pre-selected Samples for Abbott (Generic JR) |
| 349651 | 1200 | 375 | 825 | Performance Evaluation of Elecsys EBV IgM, Elecsys EBV VCA IgG, Elecsys EBV EBNA IgG on the cobas e 411 Immunoassay Analyzer _ RD003522 |
| 349332 | 200 | 45 | 155 | Venous Whole Blood and Capillary whole blood for Pre-Clinical Evaluation of the Xpert Hemorrhagic Fever Test_Protocol 259B2 |
| 349032 | 14000 | 146 | 13854 | Comparator Method Testing Aptima and Alinity m |
| 345393 | 1000 | 1066 | -66 | Prospective Collection Symptomatic Donors One or more flu-like symptoms such as: fever, cough, sore throat, runny or stuffy nose, muscle or body aches, headache, fatigue, vomiting, or diarrhea, with symptom onset within the past 7 calendar days AND/OR One or more COVID-19 symptoms such as: fever, dry cough, fatigue, loss of appetite, loss of smell or taste, body ache, or shortness of breath, with symptom onset within the past 7 calendar days AND/OR Subject has had a rapid positive COVID-19, flu A or flu B result in the past 48 hours, and symptom onset occurred within the past 4 calendar days, OR Subject has had a rapid positive COVID-19, flu A, or flu B result in the past 48 hours and has not experienced symptom onset to date. |
| 344846 | 300 | 71 | 229 | Protocol: LIA-RESP-569 (RD006493)_Testing services for archived (frozen) samples received at BCW. |
| 344240 | 60 | 7 | 53 | Nasal Swab Collection from FluA/FluB Positive Donors |
| 342645 | 1000 | 838 | 162 | Protocol: cX8-MPLX-577 (RD006700)_Testing services for archived (frozen) samples received at BCW. |
| 342354 | 60 | 10 | 50 | Prospective Collection for Positive Flu A, Flu B, RSV or Covid Donors from BCW-PR |
| 341447 | 30 | 20 | 10 | Prospective Collection for Positive SARS-CoV-2 Donors |
| 341446 | 30 | 1 | 29 | Prospective Collection for Positive RSV Donors |
| 341445 | 60 | 7 | 53 | Prospective Collection for Positive Flu A and Flu B Donors |
| 340975 | 450 | 350 | 100 | Protocol: LIA-RESP-569 Collection & Testing (RD006493) of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections |
| 340639 | 1000 | 565 | 435 | Protocol: COL-RESP-528_Testeng services for samples collected at external facilities |
| 340638 | 1000 | 591 | 409 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami |
| 339042 | 159 | 33 | 126 | HxV-VL Testing in Abbott m2000 |
| 335726 | 100 | 5 | 95 | SARS-CoV-2, Flu A, Flu B, and RSV Positive Nasal, Oropharyngeal, Nasopharyngeal and Blood Collection Protocol |
| 329522 | 4338 | 8647 | -4309 | Disposition of BioRepository Samples -Urine and Plasma Negative samples from Talents |
| 327905 | 50 | 20 | 30 | Serum and Plasma samples from Pregnant donors with a high risk of HSV-2 Infection. |
| 324678 | 32 | 3062 | -3030 | Samples selected from Siemens Biorepository to ship out to indicated locations. |
| 316965 | 100 | 26 | 74 | HxV-VL Testing in Abbott m2000 |
| 293648 | 30 | 13 | 17 | Prospective Collection for subjects with CoV-2, Flu A, Flu B, RSV |
| 292590 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Nasal Swab, Pharyngeal Swab, Vaginal Swab, Rectal Swab, Lesion Swab, Saliva Sample and/or Blood Samples from a positive or suspected positive D/Ps with Monkeypox |
| 283190 | 200 | 113 | 87 | Protocol No. LIA-STI-250 - cobas CT/NG/MG Nucleic acid test for use on the cobas Liat System: Feasibility Performance Evaluation |
| 282610 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Sample Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 266931 | 120 | 17 | 103 | PAS-19SUST053 Testing HBV VL (Abbott & Hologic) |
| 251350 | 100 | 44 | 56 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
| 242206 | 5000 | 27712 | -22712 | COVID-19 Testing |
| 239188 | 500 | 0 | 500 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 227994 | 130 | 5 | 125 | PAS-19SUST054 - HCV |
| 225611 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 224514 | 600 | 76 | 524 | Initiative to Screen Potential Study Candidates (SUST) |
| 190737 | 5000 | 95 | 4905 | SARS-CoV-2 Survey (PT) |
| 182696 | 1000 | 355 | 645 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections |
| 175121 | 1000 | 27 | 973 | CBC Initiative |
| 173768 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects |
| 152854 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 151681 | 5000 | 3 | 4997 | Refer to Processing Instructions @ Attachment Tab |
| 149547 | 5000 | 390 | 4610 | Refer to Processing Instructions @ Attachment Tab TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB |
| 148791 | 5000 | 56 | 4944 | Refer to Processing Instructions @ Attachment Tab |
| 145574 | 5000 | 165 | 4835 | Refer to Processing Instructions @ Attachment Tab |
| 144620 | 5000 | 79 | 4921 | Refer to Processing Instructions @ Attachment Tab |
| 142755 | 5000 | 167 | 4833 | Refer to Processing Instructions @ Attachment Tab |
| 141914 | 1000 | 7 | 993 | HIV Initiative |
| 141493 | 5000 | 75 | 4925 | HCV Viral Load and Genotype Survey (PT) |
| 141491 | 5000 | 30 | 4970 | HBV Viral Load Survey (PT) |
| 141490 | 5000 | 90 | 4910 | HIV Viral Load Survey (PT) |
| 140923 | 5000 | 161 | 4839 | Refer to Processing Instructions @ Attachment Tab |
| 140922 | 5000 | 75 | 4925 | Refer to Processing Instructions @ Attachment Tab |
| 140530 | 5000 | 10 | 4990 | Rubella IgG (AAB - PT) |
| 140528 | 5000 | 6 | 4994 | ToRCH (AAB - PT) |
| 139409 | 5000 | 171 | 4829 | Pregnancy (PT) |
| 137933 | 5000 | 0 | 5000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
| 137683 | 930 | 235 | 695 | Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations |
| 129688 | 200 | 163 | 37 | EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia |
| 129538 | 1000 | 309 | 691 | RPR Initiative |
| 128402 | 1000 | 73 | 927 | CBC Initiative |
| 124266 | 5000 | 143 | 4857 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire |
| 122931 | 5000 | 4092 | 908 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 122654 | 5000 | 171 | 4829 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland |
| 120851 | 140 | 26 | 114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 109382 | 100 | 32 | 68 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
| 109381 | 300 | 6 | 294 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 108692 | 1000 | 1268 | -268 | HxV Testing Initiative |
| 102419 | 1000 | 681 | 319 | Samples on hold for future shipments to China |
| 98830 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples |
| 98084 | 1000 | 576 | 424 | CBC Qualifying Job Request |
| 96278 | 195 | 185 | 10 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 96055 | 40 | 2275 | -2235 | Hologic Panels for HIV and HCV |
| 94841 | 500 | 1 | 499 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR |
| 80997 | 5000 | 428 | 4572 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
| 78138 | 300 | 140 | 160 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 78137 | 300 | 414 | -114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
| 74261 | 10000 | 0 | 10000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 68258 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 63868 | 1000 | 1585 | -585 | Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau |
| 56717 | 20000 | 0 | 20000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples |
| 55075 | 10000 | 28 | 9972 | Beta HCG Matched Set Prospective Blood Collection Protocol |
| 54664 | 200 | 148 | 52 | Random Cadaveric Samples |
| 27615 | 15000 | 633 | 14367 | Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World |
| 26761 | 10000 | 482 | 9518 | HIV Positive Time Stability Whole Blood Collection Protocol |
| 10694 | 3000 | 2234 | 766 | HCV Longitudinal Prospective Blood Collection Protocol |
| 10693 | 3000 | 369 | 2631 | HBV Multi-Point Prospective Blood Collection Protocol |
| 8568 | 300 | 1777 | -1477 | Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV) |
BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.
You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.
